{"id":10,"date":"2026-04-22T13:22:54","date_gmt":"2026-04-22T13:22:54","guid":{"rendered":"https:\/\/azstaging2.wpenginepowered.com\/?page_id=10"},"modified":"2026-04-22T13:40:05","modified_gmt":"2026-04-22T13:40:05","slug":"science","status":"publish","type":"page","link":"https:\/\/azuriyapharma.co\/?page_id=10","title":{"rendered":"Science"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n\n\n\n\n\nScience & Pipeline \u2014 Azuriya Pharma<\/title>\n<meta name=\"description\" content=\"APX3330 is a first-in-class oral APE1\/Ref-1 inhibitor that modulates upstream master transcription factors driving IBD \u2014 NF-\u03baB, HIF-1\u03b1, STAT3, and AP-1.\">\n<link rel=\"icon\" href=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\">\n<style>\n\/* ============================================================\n Azuriya Pharma \u2014 Website Design System\n Derived from the Azuriya logo: indigo \/ emerald \/ violet gradient\n ============================================================ *\/\n\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Fraunces:ital,opsz,wght@0,9..144,300..900;1,9..144,300..900&family=Manrope:wght@300;400;500;600;700;800&family=JetBrains+Mono:wght@400;500;600&display=swap');\n\n:root {\n \/* === BRAND CORE (from logo) === *\/\n --indigo: #1C1691; \/* Primary \u2014 \"Azuriya\" wordmark *\/\n --indigo-deep: #14107A; \/* Hover \/ pressed *\/\n --ink: #0B0A4E; \/* Deep background for hero \/ footer *\/\n --emerald: #00A03C; \/* Secondary \u2014 green arc *\/\n --emerald-bright:#14BE54; \/* Hover highlight *\/\n --violet: #8B4FD8; \/* Accent \u2014 gradient start *\/\n --magenta: #C850DC; \/* Accent \u2014 gradient end *\/\n\n \/* === TINTS & SURFACES === *\/\n --cloud: #F7F8FC;\n --lavender: #F0EBFA;\n --mint: #E6F7EC;\n --white: #FFFFFF;\n\n \/* === TEXT === *\/\n --ink-body: #1A1A2E; \/* body text \u2014 indigo-tinted charcoal *\/\n --ink-muted: #555566;\n --ink-subtle: #8A8A9C;\n\n \/* === LINES === *\/\n --line: #E4E4F0;\n --line-strong: #C8C8DC;\n\n \/* === EFFECTS === *\/\n --gradient-accent: linear-gradient(90deg, var(--violet) 0%, var(--magenta) 100%);\n --gradient-brand: linear-gradient(135deg, var(--indigo) 0%, var(--violet) 100%);\n --gradient-hero: linear-gradient(135deg, #0B0A4E 0%, #1C1691 60%, #2E1E8C 100%);\n\n --shadow-sm: 0 1px 2px rgba(11,10,78,0.04), 0 1px 3px rgba(11,10,78,0.06);\n --shadow-md: 0 4px 12px rgba(11,10,78,0.06), 0 8px 24px rgba(11,10,78,0.04);\n --shadow-lg: 0 12px 32px rgba(11,10,78,0.08), 0 24px 64px rgba(11,10,78,0.06);\n\n \/* === RADII === *\/\n --r-sm: 4px;\n --r-md: 8px;\n --r-lg: 14px;\n --r-xl: 22px;\n\n \/* === TYPE SCALE === *\/\n --f-display: 'Fraunces', 'Georgia', serif;\n --f-sans: 'Manrope', -apple-system, BlinkMacSystemFont, sans-serif;\n --f-mono: 'JetBrains Mono', 'SF Mono', Menlo, monospace;\n}\n\n\/* ========== RESET ========== *\/\n*, *::before, *::after { box-sizing: border-box; }\nhtml { -webkit-text-size-adjust: 100%; scroll-behavior: smooth; }\nbody {\n margin: 0;\n font-family: var(--f-sans);\n font-size: 17px;\n line-height: 1.65;\n color: var(--ink-body);\n background: var(--white);\n font-feature-settings: 'ss01', 'cv11';\n -webkit-font-smoothing: antialiased;\n -moz-osx-font-smoothing: grayscale;\n}\n@media (min-width: 1600px) {\n body { font-size: 18px; }\n}\n@media (max-width: 640px) {\n body { font-size: 16px; line-height: 1.6; }\n}\nimg { max-width: 100%; display: block; }\na { color: var(--indigo); text-decoration: none; transition: color .15s ease; }\na:hover { color: var(--violet); }\nbutton { font-family: inherit; cursor: pointer; }\n\n\/* ========== TYPOGRAPHY ========== *\/\nh1, h2, h3, h4 {\n font-family: var(--f-display);\n font-weight: 500;\n line-height: 1.12;\n letter-spacing: -0.02em;\n color: var(--ink);\n margin: 0 0 .5em;\n font-variation-settings: 'opsz' 144;\n}\nh1 { font-size: clamp(2.6rem, 5.5vw, 5rem); line-height: 1.06; }\nh2 { font-size: clamp(2rem, 4vw, 3.2rem); line-height: 1.12; }\nh3 { font-size: clamp(1.4rem, 2.4vw, 1.75rem); font-family: var(--f-sans); font-weight: 700; letter-spacing: -0.01em; line-height: 1.25; }\nh4 { font-size: 1.15rem; font-family: var(--f-sans); font-weight: 600; letter-spacing: 0; }\n\n.eyebrow {\n font-family: var(--f-sans);\n font-size: .88rem;\n font-weight: 700;\n text-transform: uppercase;\n letter-spacing: .18em;\n color: var(--emerald);\n display: inline-flex;\n align-items: center;\n gap: .55rem;\n}\n.eyebrow::before {\n content: '';\n display: inline-block;\n width: 22px;\n height: 1px;\n background: var(--emerald);\n}\n\n.lead { font-size: clamp(1.15rem, 1.4vw, 1.4rem); line-height: 1.55; color: var(--ink-muted); max-width: 62ch; }\n.mono { font-family: var(--f-mono); font-size: .92em; letter-spacing: -.01em; }\n\n\/* Italic emphasis in serif headlines gets a violet tint *\/\nh1 em, h2 em, .serif em {\n font-style: italic;\n font-weight: 400;\n background: var(--gradient-accent);\n -webkit-background-clip: text;\n background-clip: text;\n -webkit-text-fill-color: transparent;\n}\n\n\/* ========== LAYOUT ========== *\/\n.wrap { max-width: 1320px; margin: 0 auto; padding: 0 32px; }\n.narrow { max-width: 960px; margin: 0 auto; padding: 0 32px; }\n.section { padding: clamp(4rem, 8vw, 8rem) 0; }\n.section-sm { padding: clamp(2.5rem, 5vw, 4.5rem) 0; }\n@media (max-width: 640px) {\n .wrap, .narrow { padding: 0 20px; }\n}\n\n\/* ========== NAV ========== *\/\n.nav {\n position: sticky; top: 0; z-index: 50;\n background: rgba(255,255,255,.88);\n backdrop-filter: saturate(180%) blur(12px);\n -webkit-backdrop-filter: saturate(180%) blur(12px);\n border-bottom: 1px solid var(--line);\n}\n.nav-inner {\n max-width: 1320px; margin: 0 auto;\n padding: 20px 32px;\n display: flex; align-items: center; justify-content: space-between;\n gap: 32px;\n}\n.nav-brand {\n display: flex; align-items: center; gap: 10px;\n text-decoration: none;\n}\n.nav-brand img { height: 44px; width: auto; }\n.nav-links {\n display: flex; gap: 32px; align-items: center;\n list-style: none; margin: 0; padding: 0;\n}\n.nav-links a {\n font-size: 1.02rem;\n font-weight: 500;\n color: var(--ink-body);\n position: relative;\n padding: 4px 0;\n}\n.nav-links a:hover { color: var(--indigo); }\n.nav-links a.is-active { color: var(--indigo); }\n.nav-links a.is-active::after {\n content: ''; position: absolute; left: 0; right: 0; bottom: -4px;\n height: 2px;\n background: var(--gradient-accent);\n border-radius: 2px;\n}\n.nav-cta {\n padding: 12px 22px;\n border-radius: 999px;\n background: var(--indigo);\n color: var(--white) !important;\n font-weight: 600;\n font-size: .98rem;\n transition: all .15s ease;\n}\n.nav-cta:hover { background: var(--indigo-deep); transform: translateY(-1px); }\n\n.nav-toggle { display: none; background: none; border: 0; padding: 6px; cursor: pointer; }\n.nav-toggle svg { width: 28px; height: 28px; color: var(--indigo); }\n\n\/* Mobile drawer: revealed when .nav has .is-open *\/\n.nav-mobile {\n display: none;\n border-top: 1px solid var(--line);\n background: var(--white);\n padding: 16px 32px 24px;\n}\n.nav-mobile ul { list-style: none; margin: 0; padding: 0; }\n.nav-mobile li { border-bottom: 1px solid var(--line); }\n.nav-mobile li:last-child { border-bottom: 0; }\n.nav-mobile a {\n display: block;\n padding: 16px 0;\n font-size: 1.12rem;\n font-weight: 500;\n color: var(--ink);\n}\n.nav-mobile a:hover, .nav-mobile a.is-active { color: var(--indigo); }\n.nav-mobile .nav-cta {\n display: inline-block;\n margin-top: 20px;\n color: var(--white) !important;\n}\n.nav.is-open .nav-mobile { display: block; }\n\n@media (max-width: 1024px) {\n .nav-links { display: none; }\n .nav-toggle { display: block; }\n .nav-inner > .nav-cta { display: none; } \/* Contact CTA moves into drawer *\/\n}\n@media (max-width: 640px) {\n .nav-inner { padding: 16px 20px; }\n .nav-brand img { height: 38px; }\n .nav-mobile { padding: 16px 20px 24px; }\n}\n\n\/* ========== BUTTONS ========== *\/\n.btn {\n display: inline-flex; align-items: center; gap: 8px;\n padding: 16px 28px;\n border-radius: 999px;\n font-weight: 600;\n font-size: 1rem;\n text-decoration: none;\n transition: all .18s ease;\n border: 0;\n}\n.btn-primary { background: var(--indigo); color: var(--white); }\n.btn-primary:hover { background: var(--indigo-deep); color: var(--white); transform: translateY(-1px); box-shadow: var(--shadow-md); }\n\n.btn-emerald { background: var(--emerald); color: var(--white); }\n.btn-emerald:hover { background: var(--emerald-bright); color: var(--white); transform: translateY(-1px); }\n\n.btn-ghost {\n background: transparent;\n color: var(--indigo);\n border: 1.5px solid var(--line-strong);\n}\n.btn-ghost:hover { border-color: var(--indigo); background: var(--lavender); color: var(--indigo); }\n\n.btn-light {\n background: rgba(255,255,255,0.1);\n color: var(--white);\n border: 1.5px solid rgba(255,255,255,0.25);\n backdrop-filter: blur(8px);\n}\n.btn-light:hover { background: rgba(255,255,255,0.18); color: var(--white); border-color: rgba(255,255,255,0.5); }\n\n\/* ========== HERO ========== *\/\n.hero {\n position: relative;\n background: var(--gradient-hero);\n color: var(--white);\n padding: clamp(5rem, 10vw, 8rem) 0 clamp(4rem, 8vw, 6rem);\n overflow: hidden;\n}\n.hero::before {\n \/* subtle molecular network texture *\/\n content: '';\n position: absolute; inset: 0;\n background-image:\n radial-gradient(circle at 20% 30%, rgba(139,79,216,0.18) 0%, transparent 40%),\n radial-gradient(circle at 80% 70%, rgba(0,160,60,0.12) 0%, transparent 45%),\n radial-gradient(circle at 50% 100%, rgba(200,80,220,0.10) 0%, transparent 50%);\n pointer-events: none;\n}\n.hero::after {\n content: '';\n position: absolute; inset: 0;\n background-image: url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg' width='160' height='160' viewBox='0 0 160 160'><g fill='none' stroke='white' stroke-opacity='0.05' stroke-width='1'><circle cx='80' cy='80' r='3'\/><circle cx='20' cy='40' r='2'\/><circle cx='140' cy='120' r='2'\/><circle cx='40' cy='130' r='2.5'\/><circle cx='120' cy='30' r='2.5'\/><path d='M80 80 L20 40 M80 80 L140 120 M80 80 L40 130 M80 80 L120 30'\/><\/g><\/svg>\");\n background-size: 320px 320px;\n opacity: .5;\n pointer-events: none;\n}\n.hero > .wrap { position: relative; z-index: 1; }\n.hero h1 { color: var(--white); }\n.hero .eyebrow { color: #6FE5A1; }\n.hero .eyebrow::before { background: #6FE5A1; }\n.hero .lead { color: rgba(255,255,255,.85); font-size: clamp(1.2rem, 1.5vw, 1.45rem); max-width: 58ch; }\n\n\/* ========== CARD \/ PANEL ========== *\/\n.card {\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n padding: 28px;\n transition: all .2s ease;\n}\n.card:hover { border-color: var(--line-strong); box-shadow: var(--shadow-md); transform: translateY(-2px); }\n.card-tint-lav { background: var(--lavender); border-color: transparent; }\n.card-tint-mint { background: var(--mint); border-color: transparent; }\n\n\/* ========== STAT STRIP ========== *\/\n.stats {\n display: grid;\n grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));\n gap: 0;\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n overflow: hidden;\n background: var(--white);\n}\n.stat {\n padding: 40px 32px;\n border-right: 1px solid var(--line);\n position: relative;\n}\n.stat:last-child { border-right: 0; }\n.stat-value {\n font-family: var(--f-display);\n font-size: clamp(2.4rem, 4.5vw, 3.6rem);\n font-weight: 500;\n line-height: 1;\n color: var(--indigo);\n letter-spacing: -0.03em;\n margin-bottom: 10px;\n}\n.stat-label {\n font-size: .88rem;\n text-transform: uppercase;\n letter-spacing: .12em;\n color: var(--ink-muted);\n font-weight: 600;\n}\n.stat-note { font-size: .95rem; color: var(--ink-muted); margin-top: 6px; }\n@media (max-width: 720px) {\n .stat { padding: 28px 24px; border-right: 0; border-bottom: 1px solid var(--line); }\n .stat:last-child { border-bottom: 0; }\n}\n\n\/* ========== PILLAR GRID ========== *\/\n.pillars {\n display: grid;\n grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));\n gap: 24px;\n}\n.pillar {\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n padding: 32px;\n position: relative;\n transition: all .2s ease;\n}\n.pillar:hover { border-color: var(--indigo); transform: translateY(-3px); box-shadow: var(--shadow-md); }\n.pillar-num {\n font-family: var(--f-mono);\n font-size: .88rem;\n color: var(--violet);\n font-weight: 600;\n margin-bottom: 12px;\n letter-spacing: .02em;\n}\n.pillar-title {\n font-family: var(--f-display);\n font-size: clamp(1.4rem, 1.8vw, 1.65rem);\n font-weight: 500;\n letter-spacing: -0.015em;\n color: var(--ink);\n margin: 0 0 14px;\n line-height: 1.15;\n}\n.pillar-body { font-size: 1rem; color: var(--ink-muted); line-height: 1.6; }\n@media (max-width: 640px) {\n .pillars { grid-template-columns: 1fr; gap: 16px; }\n .pillar { padding: 24px; }\n}\n\n\/* ========== TABLE ========== *\/\n.tbl-wrap { overflow-x: auto; -webkit-overflow-scrolling: touch; margin: 0 -4px; padding: 0 4px; }\n.tbl {\n width: 100%;\n border-collapse: collapse;\n font-size: 1rem;\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-md);\n overflow: hidden;\n}\n.tbl th {\n text-align: left;\n padding: 16px 20px;\n background: var(--cloud);\n border-bottom: 1px solid var(--line);\n font-size: .82rem;\n text-transform: uppercase;\n letter-spacing: .1em;\n color: var(--ink-muted);\n font-weight: 700;\n}\n.tbl td {\n padding: 16px 20px;\n border-bottom: 1px solid var(--line);\n vertical-align: top;\n}\n.tbl tr:last-child td { border-bottom: 0; }\n.tbl tr:hover td { background: var(--cloud); }\n@media (max-width: 640px) {\n .tbl { font-size: .95rem; min-width: 560px; }\n .tbl th, .tbl td { padding: 12px 14px; }\n}\n\n\/* ========== BADGES & CHIPS ========== *\/\n.badge {\n display: inline-flex; align-items: center; gap: 5px;\n padding: 4px 11px;\n font-size: .78rem;\n font-weight: 700;\n letter-spacing: .08em;\n text-transform: uppercase;\n border-radius: 4px;\n}\n.badge-new { background: var(--emerald); color: var(--white); }\n.badge-indigo { background: var(--lavender); color: var(--indigo); }\n.badge-violet { background: linear-gradient(90deg, rgba(139,79,216,.15), rgba(200,80,220,.15)); color: var(--violet); }\n.badge-outline{ background: transparent; color: var(--ink-muted); border: 1px solid var(--line-strong); }\n\n.chip {\n display: inline-flex; align-items: center; gap: 5px;\n padding: 6px 14px;\n font-size: .88rem;\n font-weight: 500;\n border-radius: 999px;\n background: var(--cloud);\n border: 1px solid var(--line);\n color: var(--ink-body);\n}\n.chip.is-active { background: var(--indigo); color: var(--white); border-color: var(--indigo); }\n.chip:hover:not(.is-active) { background: var(--lavender); border-color: var(--violet); color: var(--indigo); cursor: pointer; }\n\n\/* ========== SECTION DIVIDER ========== *\/\n.divider {\n height: 2px;\n background: var(--gradient-accent);\n border-radius: 2px;\n width: 60px;\n margin: 0 0 24px;\n}\n\n\/* ========== FOOTER ========== *\/\n.foot {\n background: var(--ink);\n color: rgba(255,255,255,.78);\n padding: 72px 0 32px;\n margin-top: 72px;\n}\n.foot a { color: rgba(255,255,255,.78); }\n.foot a:hover { color: var(--white); }\n.foot-grid {\n display: grid;\n grid-template-columns: 2fr 1fr 1fr 1fr;\n gap: 56px;\n margin-bottom: 56px;\n}\n.foot h4 {\n color: var(--white);\n font-size: .85rem;\n text-transform: uppercase;\n letter-spacing: .15em;\n margin: 0 0 18px;\n font-weight: 700;\n}\n.foot ul { list-style: none; padding: 0; margin: 0; }\n.foot ul li { margin-bottom: 12px; font-size: 1rem; }\n.foot-brand img { height: 54px; margin-bottom: 20px; filter: brightness(0) invert(1) opacity(.88); }\n.foot-copy {\n padding-top: 32px;\n border-top: 1px solid rgba(255,255,255,.12);\n font-size: .9rem;\n display: flex;\n justify-content: space-between;\n flex-wrap: wrap;\n gap: 16px;\n}\n@media (max-width: 900px) {\n .foot-grid { grid-template-columns: 1fr 1fr; gap: 36px; }\n}\n@media (max-width: 520px) {\n .foot-grid { grid-template-columns: 1fr; gap: 32px; }\n .foot { padding: 56px 0 24px; }\n}\n\n\/* ========== UTILS ========== *\/\n.grid-2 { display: grid; grid-template-columns: 1fr 1fr; gap: 56px; }\n.grid-3 { display: grid; grid-template-columns: repeat(3, 1fr); gap: 28px; }\n.grid-4 { display: grid; grid-template-columns: repeat(4, 1fr); gap: 24px; }\n@media (max-width: 1024px) {\n .grid-4 { grid-template-columns: repeat(2, 1fr); }\n}\n@media (max-width: 800px) {\n .grid-2, .grid-3 { grid-template-columns: 1fr; gap: 32px; }\n}\n@media (max-width: 640px) {\n .grid-4 { grid-template-columns: 1fr; gap: 16px; }\n}\n\n.text-center { text-align: center; }\n.mt-1 { margin-top: 8px; } .mt-2 { margin-top: 16px; } .mt-3 { margin-top: 24px; } .mt-4 { margin-top: 40px; } .mt-5 { margin-top: 64px; }\n.mb-1 { margin-bottom: 8px; } .mb-2 { margin-bottom: 16px; } .mb-3 { margin-bottom: 24px; } .mb-4 { margin-bottom: 40px; }\n\n\/* Tint backgrounds for sections *\/\n.bg-cloud { background: var(--cloud); }\n.bg-lavender { background: var(--lavender); }\n.bg-mint { background: var(--mint); }\n.bg-ink { background: var(--ink); color: var(--white); }\n.bg-ink h1, .bg-ink h2, .bg-ink h3 { color: var(--white); }\n\n\/* Checkmark list *\/\n.checklist { list-style: none; padding: 0; margin: 0; }\n.checklist li {\n padding: 10px 0 10px 34px;\n position: relative;\n line-height: 1.55;\n font-size: 1rem;\n}\n.checklist li::before {\n content: '';\n position: absolute; left: 0; top: 14px;\n width: 20px; height: 20px;\n background: var(--emerald);\n border-radius: 50%;\n background-image: url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg' viewBox='0 0 12 12'><path fill='none' stroke='white' stroke-width='2' stroke-linecap='round' stroke-linejoin='round' d='M2.5 6.5 L5 9 L9.5 3.5'\/><\/svg>\");\n background-size: 13px 13px;\n background-position: center;\n background-repeat: no-repeat;\n}\n\n\/* Forms *\/\n.form-row { display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-bottom: 20px; }\n@media (max-width: 600px) { .form-row { grid-template-columns: 1fr; gap: 16px; margin-bottom: 16px; } }\n\n.field {\n display: block;\n width: 100%;\n padding: 15px 17px;\n font-family: inherit;\n font-size: 1.02rem;\n color: var(--ink-body);\n background: var(--white);\n border: 1.5px solid var(--line-strong);\n border-radius: var(--r-md);\n transition: border-color .15s ease;\n}\n.field:focus { outline: 0; border-color: var(--indigo); box-shadow: 0 0 0 3px rgba(28,22,145,.12); }\n.label {\n display: block;\n font-size: .92rem;\n font-weight: 600;\n color: var(--ink-body);\n margin-bottom: 8px;\n letter-spacing: .01em;\n}\ntextarea.field { min-height: 160px; resize: vertical; }\n\n\/* Scientific accent \u2014 small molecule chip *\/\n.mol-chip {\n display: inline-flex; align-items: baseline; gap: 6px;\n padding: 4px 11px;\n background: var(--ink);\n color: var(--white);\n border-radius: 4px;\n font-family: var(--f-mono);\n font-size: .85rem;\n font-weight: 500;\n letter-spacing: .02em;\n}\n\n\/* Accordion \/ expandable *\/\n.timeline {\n position: relative;\n padding-left: 32px;\n}\n.timeline::before {\n content: ''; position: absolute;\n left: 7px; top: 6px; bottom: 6px;\n width: 2px;\n background: linear-gradient(180deg, var(--indigo) 0%, var(--violet) 50%, var(--magenta) 100%);\n border-radius: 2px;\n}\n.timeline-item { position: relative; padding-bottom: 32px; }\n.timeline-item::before {\n content: ''; position: absolute;\n left: -32px; top: 6px;\n width: 16px; height: 16px;\n background: var(--white);\n border: 3px solid var(--indigo);\n border-radius: 50%;\n}\n.timeline-item:last-child { padding-bottom: 0; }\n.timeline-date {\n font-family: var(--f-mono);\n font-size: .88rem;\n color: var(--violet);\n font-weight: 600;\n text-transform: uppercase;\n letter-spacing: .06em;\n margin-bottom: 6px;\n}\n.timeline-title { font-weight: 700; font-size: 1.15rem; color: var(--ink); margin-bottom: 6px; }\n.timeline-body { color: var(--ink-muted); font-size: 1rem; line-height: 1.6; }\n\n\/* Legal\/disclaimer microcopy *\/\n.fine { font-size: .88rem; color: var(--ink-muted); line-height: 1.6; }\n\n\/* ========== RESPONSIVE FINE-TUNING ========== *\/\n\n\/* Tablet tuning *\/\n@media (max-width: 1024px) {\n .hero { padding: clamp(4rem, 8vw, 6rem) 0 clamp(3rem, 6vw, 5rem); }\n}\n\n\/* Mobile tuning \u2014 < 640px *\/\n@media (max-width: 640px) {\n h1 { font-size: clamp(2.1rem, 9vw, 3rem); }\n h2 { font-size: clamp(1.65rem, 6.5vw, 2.2rem); }\n h3 { font-size: 1.25rem; }\n .lead { font-size: 1.08rem; }\n .hero { padding: 3.5rem 0 3rem; }\n .hero .lead { font-size: 1.08rem; }\n .section { padding: 3.5rem 0; }\n .section-sm { padding: 2.5rem 0; }\n .card, .pillar { padding: 24px; }\n .btn { padding: 14px 22px; font-size: .95rem; }\n .stat-value { font-size: clamp(2.2rem, 10vw, 2.8rem); }\n}\n\n\/* Small mobile \u2014 < 380px *\/\n@media (max-width: 380px) {\n body { font-size: 15px; }\n h1 { font-size: 2rem; }\n .wrap, .narrow { padding: 0 16px; }\n .hero { padding: 3rem 0 2.5rem; }\n}\n\n\/* Safety: horizontal overflow prevention *\/\nhtml, body { overflow-x: hidden; max-width: 100%; }\nimg, svg, video { max-width: 100%; height: auto; }\ntable { max-width: 100%; }\n\n<\/style>\n<\/head>\n<body>\n\n<header class=\"nav\">\n <div class=\"nav-inner\">\n <a class=\"nav-brand\" href=\"index.html\"><img decoding=\"async\" src=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\" alt=\"Azuriya Pharma\"><\/a>\n <nav><ul class=\"nav-links\">\n <li><a href=\"index.html\">Home<\/a><\/li>\n <li><a href=\"science.html\" class=\"is-active\">Science & Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <li><a href=\"about.html\">About<\/a><\/li>\n <li><a href=\"investors.html\">Investors<\/a><\/li>\n <\/ul><\/nav>\n <a class=\"nav-cta\" href=\"contact.html\">Contact<\/a>\n <\/div>\n\n <div class=\"nav-mobile\">\n <ul>\n <li><a href=\"index.html\">Home<\/a><\/li>\n <li><a href=\"science.html\" class=\"is-active\">Science & Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <li><a href=\"about.html\">About<\/a><\/li>\n <li><a href=\"investors.html\">Investors<\/a><\/li>\n <\/ul>\n <a class=\"nav-cta\" href=\"contact.html\">Contact<\/a>\n <\/div>\n<\/header>\n\n<!-- HERO -->\n<section class=\"hero\" style=\"padding:clamp(4rem,7vw,6rem) 0;\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Science<\/span>\n <h1 style=\"margin-top:22px;\">Upstream modulation.<br><em>One target. Many diseases.<\/em><\/h1>\n <p class=\"lead\" style=\"margin-top:22px;\">\n APX3330 is a first-in-class oral inhibitor of APE1\/Ref-1 \u2014 the master regulator of\n transcription factors central to IBD disease progression. The mechanism fills gaps in\n current standard of care with future opportunities in cancer, diabetic retinopathy,\n rheumatoid arthritis, and neurodegenerative disease.\n <\/p>\n <\/div>\n<\/section>\n\n<!-- MECHANISM OF ACTION -->\n<section class=\"section\">\n <div class=\"wrap\">\n <div style=\"max-width:640px;\">\n <span class=\"eyebrow\">Mechanism of Action<\/span>\n <h2 class=\"mt-2\">A novel upstream point of intervention.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <p class=\"lead mt-3\">\n APX3330's upstream mechanism enables combination with every approved IBD class \u2014\n including JAK, TNF-\u03b1, IL-23, TL1A, and \u03b14\u03b27 \u2014 without mechanistic redundancy or\n additive immunosuppression risk. <span class=\"mono\">NF-\u03baB<\/span>, for example, is a\n master \"key\" transcription factor modulating inflammation, immune response, and cell\n survival simultaneously.\n <\/p>\n <\/div>\n\n <!-- MOA FUNNEL DIAGRAM -->\n <div class=\"mt-5\" style=\"background:var(--white); border:1px solid var(--line); border-radius:var(--r-xl); padding:clamp(32px,5vw,56px); margin-top:48px;\">\n <div style=\"text-align:center; margin-bottom:36px;\">\n <span class=\"mol-chip\">APX3330 \u00b7 APE1\/Ref-1 inhibitor<\/span>\n <\/div>\n <div style=\"display:flex; justify-content:center; margin-bottom:24px;\">\n <svg width=\"100%\" height=\"auto\" viewBox=\"0 0 600 80\" style=\"max-width:600px;\">\n <defs>\n <linearGradient id=\"arrowg\" x1=\"0\" x2=\"1\" y1=\"0\" y2=\"0\">\n <stop offset=\"0%\" stop-color=\"#1C1691\"\/>\n <stop offset=\"100%\" stop-color=\"#8B4FD8\"\/>\n <\/linearGradient>\n <\/defs>\n <line x1=\"300\" y1=\"10\" x2=\"300\" y2=\"60\" stroke=\"url(#arrowg)\" stroke-width=\"3\"\/>\n <polygon points=\"290,55 310,55 300,75\" fill=\"#8B4FD8\"\/>\n <\/svg>\n <\/div>\n\n <!-- Master TFs -->\n <div style=\"display:grid; grid-template-columns:repeat(4, 1fr); gap:14px; margin-bottom:32px;\">\n <div style=\"padding:18px; text-align:center; background:var(--lavender); border-radius:var(--r-md);\">\n <div class=\"mono\" style=\"font-weight:600; color:var(--indigo);\">NF-\u03baB<\/div>\n <div class=\"fine mt-1\">Master inflammation<\/div>\n <\/div>\n <div style=\"padding:18px; text-align:center; background:var(--mint); border-radius:var(--r-md);\">\n <div class=\"mono\" style=\"font-weight:600; color:var(--emerald);\">HIF-1\u03b1<\/div>\n <div class=\"fine mt-1\">Hypoxia \/ vascular<\/div>\n <\/div>\n <div style=\"padding:18px; text-align:center; background:var(--lavender); border-radius:var(--r-md);\">\n <div class=\"mono\" style=\"font-weight:600; color:var(--violet);\">STAT3<\/div>\n <div class=\"fine mt-1\">Cytokine signaling<\/div>\n <\/div>\n <div style=\"padding:18px; text-align:center; background:var(--lavender); border-radius:var(--r-md);\">\n <div class=\"mono\" style=\"font-weight:600; color:var(--magenta);\">AP-1<\/div>\n <div class=\"fine mt-1\">Proliferation \/ stress<\/div>\n <\/div>\n <\/div>\n\n <div style=\"text-align:center; color:var(--ink-muted); font-size:.88rem; letter-spacing:.05em; text-transform:uppercase; font-weight:600; margin-bottom:18px;\">converges on validated downstream IBD biology<\/div>\n\n <!-- Downstream -->\n <div style=\"display:grid; grid-template-columns:repeat(auto-fit, minmax(140px, 1fr)); gap:10px;\">\n <div style=\"padding:14px; text-align:center; background:var(--cloud); border:1px solid var(--line); border-radius:var(--r-md); font-size:.9rem;\">\n <strong style=\"color:var(--indigo);\">TNF-\u03b1 \/ NF-\u03baB<\/strong>\n <div class=\"fine mt-1\">Anti-TNF class<\/div>\n <\/div>\n <div style=\"padding:14px; text-align:center; background:var(--cloud); border:1px solid var(--line); border-radius:var(--r-md); font-size:.9rem;\">\n <strong style=\"color:var(--indigo);\">IL-23 \/ Th17<\/strong>\n <div class=\"fine mt-1\">Anti-IL-23 class<\/div>\n <\/div>\n <div style=\"padding:14px; text-align:center; background:var(--cloud); border:1px solid var(--line); border-radius:var(--r-md); font-size:.9rem;\">\n <strong style=\"color:var(--indigo);\">TL1A \/ remodeling<\/strong>\n <div class=\"fine mt-1\">Anti-TL1A class<\/div>\n <\/div>\n <div style=\"padding:14px; text-align:center; background:var(--cloud); border:1px solid var(--line); border-radius:var(--r-md); font-size:.9rem;\">\n <strong style=\"color:var(--indigo);\">\u03b14\u03b27 \/ trafficking<\/strong>\n <div class=\"fine mt-1\">Integrin class<\/div>\n <\/div>\n <div style=\"padding:14px; text-align:center; background:var(--cloud); border:1px solid var(--line); border-radius:var(--r-md); font-size:.9rem;\">\n <strong style=\"color:var(--indigo);\">JAK \/ STAT<\/strong>\n <div class=\"fine mt-1\">JAK inhibitor class<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n<!-- 5 PILLARS OF DISEASE IMPACT -->\n<section class=\"section bg-cloud\">\n <div class=\"wrap\">\n <div style=\"max-width:720px;\">\n <span class=\"eyebrow\">Five Domains of Disease Impact<\/span>\n <h2 class=\"mt-2\">Addressing what current therapies leave unresolved.<\/h2>\n <p class=\"lead mt-3\">\n Current IBD therapies primarily suppress downstream inflammation. They ignore key\n pathological processes including epithelial stress, oxidative injury, neuronal\n dysfunction, and systemic immune amplification. APX3330 is designed to address all five.\n <\/p>\n <\/div>\n\n <div class=\"pillars mt-5\">\n <article class=\"pillar\">\n <div class=\"pillar-num\">01<\/div>\n <h3 class=\"pillar-title\">Inflammation Control<\/h3>\n <p class=\"pillar-body\">Blocks master inflammatory transcription factors NF-\u03baB, STAT3, HIF-1\u03b1, and AP-1 \u2014 reducing proinflammatory cytokines (TNF-\u03b1, IL-6, IL-1\u03b2) and ROS overproduction that sustain chronic mucosal inflammation.<\/p>\n <\/article>\n <article class=\"pillar\">\n <div class=\"pillar-num\">02<\/div>\n <h3 class=\"pillar-title\">Barrier Integrity<\/h3>\n <p class=\"pillar-body\">Restores epithelial resilience and antimicrobial defense, stabilizing the gut mucosa and reducing permeability.<\/p>\n <\/article>\n <article class=\"pillar\">\n <div class=\"pillar-num\">03<\/div>\n <h3 class=\"pillar-title\">Neural Protection<\/h3>\n <p class=\"pillar-body\">Preserves enteric neurons and glial cells \u2014 addressing persistent dysmotility, urgency, and pain that existing therapies don't touch.<\/p>\n <\/article>\n <article class=\"pillar\">\n <div class=\"pillar-num\">04<\/div>\n <h3 class=\"pillar-title\">Oral Dosing<\/h3>\n <p class=\"pillar-body\">Daily 1\u20132\u00d7 oral dosing with an established safety profile across ~400 patients in prior clinical studies. No injectable-related adherence burden.<\/p>\n <\/article>\n <article class=\"pillar\">\n <div class=\"pillar-num\">05<\/div>\n <h3 class=\"pillar-title\">CHIP & Hematopoiesis Correction<\/h3>\n <p class=\"pillar-body\">Dials down disease-driven Ref-1 signaling to restore hematopoietic stem cell function, correct myeloid bias, and limit IBD-driven CHIP expansion and myeloid infiltration in the colon.<\/p>\n <\/article>\n <article class=\"pillar\" style=\"background:linear-gradient(135deg, var(--lavender) 0%, var(--mint) 100%); border:0;\">\n <div class=\"pillar-num\" style=\"color:var(--emerald);\">\u2197 Forward<\/div>\n <h3 class=\"pillar-title\">Future Indications<\/h3>\n <p class=\"pillar-body\">Beyond IBD: cancer, diabetic retinopathy, rheumatoid arthritis, Alzheimer's, Parkinson's, and neonatal necrotizing enterocolitis. One target, many diseases.<\/p>\n <\/article>\n <\/div>\n <\/div>\n<\/section>\n\n<!-- SAFETY -->\n<section class=\"section\">\n <div class=\"wrap\">\n <div style=\"max-width:640px;\">\n <span class=\"eyebrow\">Human Safety & Tolerability<\/span>\n <h2 class=\"mt-2\">~400 subjects \u00b7 11 trials \u00b7 chronic dosing supported.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <\/div>\n\n <div class=\"stats mt-4\">\n <div class=\"stat\">\n <div class=\"stat-value\">~400<\/div>\n <div class=\"stat-label\">Subjects Dosed<\/div>\n <div class=\"stat-note\">Across 11 Phase 1\/2 trials<\/div>\n <\/div>\n <div class=\"stat\">\n <div class=\"stat-value\">600 mg<\/div>\n <div class=\"stat-label\">RP2D Established<\/div>\n <div class=\"stat-note\">Oral daily dosing<\/div>\n <\/div>\n <div class=\"stat\">\n <div class=\"stat-value\">0<\/div>\n <div class=\"stat-label\">Treatment-Related SAEs<\/div>\n <div class=\"stat-note\">In Phase 1 oncology trial<\/div>\n <\/div>\n <div class=\"stat\">\n <div class=\"stat-value\"><5%<\/div>\n <div class=\"stat-label\">Overall AE Rate<\/div>\n <div class=\"stat-note\">vs placebo in Phase 2<\/div>\n <\/div>\n <\/div>\n\n <div class=\"mt-5\" style=\"overflow-x:auto;\">\n <table class=\"tbl\">\n <thead>\n <tr>\n <th>Program<\/th>\n <th>N<\/th>\n <th>Dose<\/th>\n <th>Duration<\/th>\n <th>Key Safety Findings<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td><strong>Phase 1 Oncology<\/strong><br><span class=\"mono\" style=\"font-size:.82rem; color:var(--ink-muted);\">NCT03375086<\/span><\/td>\n <td>19<\/td>\n <td>240\u2013720 mg\/d<\/td>\n <td>21-day cycles (to 421d)<\/td>\n <td>No SAEs; G1 fatigue most common; 1 DLT at 720 mg (G3 rash, reversible). RP2D = 600 mg\/d.<\/td>\n <\/tr>\n <tr>\n <td><strong>Phase 1 Healthy Volunteer<\/strong><br><span class=\"fine\">(Eisai)<\/span><\/td>\n <td>~100<\/td>\n <td>10\u2013600 mg\/d<\/td>\n <td>Single & multi-dose<\/td>\n <td><10% mild diarrhea vs 0% placebo; 2 reversible rashes at 600 mg (MTD). Supports chronic dosing.<\/td>\n <\/tr>\n <tr>\n <td><strong>Phase 2 Hepatitis<\/strong><br><span class=\"fine\">(Eisai, 422 patients)<\/span><\/td>\n <td>~200<\/td>\n <td>Up to 600 mg<\/td>\n <td>Multi-month<\/td>\n <td>AEs in <5% of patients, similar to placebo; favorable hepatic and renal safety. Largest chronic dataset.<\/td>\n <\/tr>\n <tr>\n <td><strong>ZETA-1 Phase 2b \u2014 Diabetic Retinopathy<\/strong><br><span class=\"mono\" style=\"font-size:.82rem; color:var(--ink-muted);\">NCT04692688<\/span><\/td>\n <td>~50<\/td>\n <td>600 mg\/d<\/td>\n <td>24 weeks<\/td>\n <td>No drug-related AEs except 2 diarrhea episodes (same patient); 5 SAEs all unrelated. Placebo-level AE profile.<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n\n <p class=\"fine mt-3\">\n <strong>Summary for IBD development:<\/strong> No significant organ toxicity (liver, heart, kidney, brain, lung).\n No vital sign abnormalities. No treatment-related SAEs in oncology trial. AE rates comparable to placebo in\n ZETA-1. Established 600 mg\/day RP2D supports proposed IBD doses (300 mg & 600 mg for Phase 2a). Clean\n profile is a critical differentiator versus JAK inhibitors (black-box warnings for VTE, MACE, malignancy) and\n TNF-\u03b1 inhibitors (serious infection risk).\n <br><br>\n Sources: Kelley et al., medRxiv 2025; Su et al., IOVS 2022 (ZETA-1); Nagakawa et al., JPET 1993 (Eisai hepatitis); Kelley Lab, IU School of Medicine.\n <\/p>\n <\/div>\n<\/section>\n\n<!-- PRECLINICAL -->\n<section class=\"section bg-lavender\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Preclinical Validation<\/span>\n <h2 class=\"mt-2\">Validated in multiple translatable IBD models.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n\n <div class=\"grid-2 mt-4\">\n <article class=\"card\" style=\"background:var(--white);\">\n <h3 style=\"color:var(--indigo);\">Winnie Mouse Model \u2014 Chronic Colitis<\/h3>\n <p class=\"fine\" style=\"margin-top:10px;\">APX3330 corrects inflammation, provides neuroprotection, and attenuates weight loss.<\/p>\n <ul class=\"checklist mt-2\" style=\"font-size:.95rem;\">\n <li>Blocks inflammation and reduces clinical symptoms<\/li>\n <li>Corrects colonic contractile activity and GI transit<\/li>\n <li>Regeneration of nerve fibers and glial cells in colon<\/li>\n <li>Prevents oxidative stress and DNA damage in myenteric neurons<\/li>\n <\/ul>\n <\/article>\n <article class=\"card\" style=\"background:var(--white);\">\n <h3 style=\"color:var(--indigo);\">DSS Mouse Model \u2014 Acute Colitis<\/h3>\n <p class=\"fine\" style=\"margin-top:10px;\">APX3330 corrects inflammation, increases colon length, and soothes intestines.<\/p>\n <ul class=\"checklist mt-2\" style=\"font-size:.95rem;\">\n <li>Decreased body weight loss, rectal prolapse, edema, bleeding<\/li>\n <li>Corrects intestinal permeability<\/li>\n <li>Normalizes GI antibacterial defense<\/li>\n <li>Published in <em>Inflamm. Bowel Dis.<\/em> 2020 \u00b7 PMID 32618996<\/li>\n <\/ul>\n <\/article>\n <\/div>\n\n <p class=\"fine mt-4\">\n APX3330 compares favorably to successful IBD MOAs across acute DSS, chronic Winnie, adoptive transfer,\n and T-cell transfer models. See full preclinical benchmarking in the data room.\n <\/p>\n <\/div>\n<\/section>\n\n<!-- PIPELINE -->\n<section class=\"section\" id=\"pipeline\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Pipeline<\/span>\n <h2 class=\"mt-2\">Late-stage program \u00b7 multiple indications.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n\n <div class=\"mt-4\" style=\"overflow-x:auto;\">\n <table class=\"tbl\">\n <thead>\n <tr>\n <th style=\"min-width:140px;\">Program<\/th>\n <th>Indication<\/th>\n <th>Preclinical<\/th>\n <th>IND-Ready<\/th>\n <th>Phase 1<\/th>\n <th>Phase 2<\/th>\n <th>Phase 3<\/th>\n <th>Notes<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td><span class=\"mol-chip\">APX3330<\/span><\/td>\n <td><strong>Ulcerative Colitis<\/strong><\/td>\n <td>\u2713<\/td>\n <td>\u2713<\/td>\n <td>\u2713<\/td>\n <td style=\"background:var(--mint); color:var(--emerald); font-weight:700;\">FOCUS \u2192 P2a\/P2b<\/td>\n <td>\u2014<\/td>\n <td class=\"fine\">Lead indication \u00b7 2027 topline P2a<\/td>\n <\/tr>\n <tr>\n <td><span class=\"mol-chip\">APX3330<\/span><\/td>\n <td><strong>Crohn's Disease<\/strong><\/td>\n <td>\u2713<\/td>\n <td>\u2713<\/td>\n <td>\u2014<\/td>\n <td>Label expansion<\/td>\n <td>\u2014<\/td>\n <td class=\"fine\">Follow-on \u00b7 single study for label expansion<\/td>\n <\/tr>\n <tr>\n <td><span class=\"mol-chip\">APX3330<\/span><\/td>\n <td><strong>Diabetic Retinopathy<\/strong><\/td>\n <td>\u2713<\/td>\n <td>\u2713<\/td>\n <td>\u2713<\/td>\n <td style=\"color:var(--violet); font-weight:600;\">Completed 2b<\/td>\n <td>\u2014<\/td>\n <td class=\"fine\">Proven safety, moderate efficacy at 6 mos<\/td>\n <\/tr>\n <tr>\n <td><span class=\"mol-chip\">APX3330<\/span><\/td>\n <td><strong>Necrotizing Enterocolitis (NEC)<\/strong><\/td>\n <td>\u2713<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td class=\"fine\">Orphan \u00b7 grants & FDA SPA pathway<\/td>\n <\/tr>\n <tr>\n <td><span class=\"mol-chip\">APX2009 \/ APX2014<\/span><\/td>\n <td><strong>TBD (2nd gen)<\/strong><\/td>\n <td>\u2713<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td class=\"fine\">Second-generation composition of matter<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n <\/div>\n<\/section>\n\n<!-- CLINICAL DEVELOPMENT PLAN -->\n<section class=\"section bg-cloud\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Clinical Development Plan<\/span>\n <h2 class=\"mt-2\">Phase 2a POC in Australia, then Phase 2b at FDA-approvable endpoints.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n\n <div class=\"grid-2 mt-4\">\n <div class=\"card\" style=\"background:var(--white);\">\n <span class=\"badge badge-indigo\">Phase 2a \u00b7 POC<\/span>\n <h3 style=\"margin-top:14px;\">Open-label proof of concept<\/h3>\n <div class=\"grid-2\" style=\"gap:18px; margin-top:20px;\">\n <div>\n <h4 style=\"font-size:.78rem; text-transform:uppercase; letter-spacing:.12em; color:var(--ink-muted); margin-bottom:6px;\">Inclusion<\/h4>\n <ul class=\"fine\" style=\"padding-left:18px;\">\n <li>Refractory UC patients<\/li>\n <li>Biologic-experienced<\/li>\n <li>Open to add-on design<\/li>\n <\/ul>\n <\/div>\n <div>\n <h4 style=\"font-size:.78rem; text-transform:uppercase; letter-spacing:.12em; color:var(--ink-muted); margin-bottom:6px;\">Structure<\/h4>\n <ul class=\"fine\" style=\"padding-left:18px;\">\n <li>10\u201320 open-label patients<\/li>\n <li>300\u2013600 mg\/day oral<\/li>\n <li>3-month endpoint (+3 extension)<\/li>\n <li>~5 Australian sites<\/li>\n <\/ul>\n <\/div>\n <\/div>\n <h4 style=\"font-size:.78rem; text-transform:uppercase; letter-spacing:.12em; color:var(--ink-muted); margin-top:18px; margin-bottom:6px;\">Endpoints<\/h4>\n <p class=\"fine\">Clinical response \u00b7 clinical remission \u00b7 endoscopic improvement \u00b7 inflammatory\/blood\/mechanistic biomarkers \u00b7 weight loss \u00b7 PROs<\/p>\n <div style=\"padding:14px; background:var(--mint); border-radius:var(--r-md); margin-top:18px;\">\n <strong style=\"color:var(--emerald);\">Budget:<\/strong> $1.5M AUD \u2192 $1M USD (60% AUS R&D saving)\n <br><span class=\"fine\">6 months to FPI \u00b7 6 months to full data (2H 2027)<\/span>\n <\/div>\n <\/div>\n\n <div class=\"card\" style=\"background:var(--white);\">\n <span class=\"badge badge-violet\">Phase 2b \u00b7 FDA-Approvable<\/span>\n <h3 style=\"margin-top:14px;\">Randomized double-blind placebo-controlled<\/h3>\n <div class=\"grid-2\" style=\"gap:18px; margin-top:20px;\">\n <div>\n <h4 style=\"font-size:.78rem; text-transform:uppercase; letter-spacing:.12em; color:var(--ink-muted); margin-bottom:6px;\">Inclusion<\/h4>\n <ul class=\"fine\" style=\"padding-left:18px;\">\n <li>Refractory UC patients<\/li>\n <li>Biologic-experienced<\/li>\n <li>Add-on design possible<\/li>\n <\/ul>\n <\/div>\n <div>\n <h4 style=\"font-size:.78rem; text-transform:uppercase; letter-spacing:.12em; color:var(--ink-muted); margin-bottom:6px;\">Structure<\/h4>\n <ul class=\"fine\" style=\"padding-left:18px;\">\n <li>150\u2013240 randomized, double-blind<\/li>\n <li>Placebo + active dose arm(s)<\/li>\n <li>3-month endpoint<\/li>\n <li>~5 AUS + 25+ AUS\/US sites<\/li>\n <\/ul>\n <\/div>\n <\/div>\n <h4 style=\"font-size:.78rem; text-transform:uppercase; letter-spacing:.12em; color:var(--ink-muted); margin-top:18px; margin-bottom:6px;\">Endpoints<\/h4>\n <p class=\"fine\">Clinical response \u00b7 clinical remission \u00b7 endoscopic improvement \u00b7 biomarkers \u00b7 PROs \u00b7 optional 6-month maintenance<\/p>\n <div style=\"padding:14px; background:var(--lavender); border-radius:var(--r-md); margin-top:18px;\">\n <strong style=\"color:var(--violet);\">Budget:<\/strong> ~$8.5M gross \u2192 $5\u20136M net\n <br><span class=\"fine\">9 months to FPI \u00b7 18\u201324 months to data<\/span>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n<!-- IP -->\n<section class=\"section\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Intellectual Property<\/span>\n <h2 class=\"mt-2\">Protected through 2044+ before PTE.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <p class=\"lead mt-2\">\n Seven patent families covering composition of matter, methods of use, and formulation \u2014\n providing extended global commercial runway.\n <\/p>\n\n <div class=\"mt-4\" style=\"overflow-x:auto;\">\n <table class=\"tbl\">\n <thead>\n <tr><th>Family<\/th><th>Patent No.<\/th><th>Scope<\/th><th>Expiry<\/th><\/tr>\n <\/thead>\n <tbody>\n <tr><td>APE1\/Ref-1 Combo Therapy<\/td><td class=\"mono\">US20190160034A1<\/td><td>Granted US \u00b7 GI inflammation claims<\/td><td><strong>2034<\/strong><\/td><\/tr>\n <tr><td>2nd-Generation Compounds<\/td><td class=\"mono\">US11,723,886 B2<\/td><td>APX2009 \/ APX2014 \u00b7 inflammation claims<\/td><td><strong>2036<\/strong><\/td><\/tr>\n <tr><td>Inflammation \/ Pain \/ IBD<\/td><td class=\"mono\">US11,351,130 B2<\/td><td>IBD claims \u00b7 DNA repair in gut\/ENS<\/td><td><strong>2038<\/strong><\/td><\/tr>\n <tr><td>Polymorphs & Salts<\/td><td class=\"mono\">US12,312,308 B2<\/td><td>Issued 05\/27\/25 \u00b7 9 countries<\/td><td style=\"background:var(--mint); color:var(--emerald); font-weight:700;\">2044<\/td><\/tr>\n <tr><td>Ca Salt Formulations<\/td><td class=\"mono\">WO 2025\/194083<\/td><td>Published \u00b7 national stage Sep 2026<\/td><td style=\"background:var(--mint); color:var(--emerald); font-weight:700;\">2045<\/td><\/tr>\n <tr><td>NEC Method of Use<\/td><td class=\"mono\">IU disclosure (2021)<\/td><td>APE1\/Ref-1 inhibition in neonatal NEC<\/td><td>2041<\/td><\/tr>\n <tr><td>IBD Method of Use<\/td><td class=\"mono\">IU filings<\/td><td>UC\/Crohn's treatment \u00b7 exclusivity<\/td><td>~2038+<\/td><\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n <p class=\"fine mt-3\">Sources: Frontage 039567\/039837; CRL-ASH 20488855\/60; \u00b9\u2074C-QWBA; IURTC Patent Portfolio; OPUS Vendor List.<\/p>\n <\/div>\n<\/section>\n\n<!-- FOOTER -->\n<footer class=\"foot\">\n <div class=\"wrap\">\n <div class=\"foot-grid\">\n <div class=\"foot-brand\">\n <img decoding=\"async\" src=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\" alt=\"Azuriya Pharma\">\n <p style=\"max-width:340px; font-size:.95rem; line-height:1.6;\">A late-stage, first-in-class oral small-molecule therapy targeting root causes of Inflammatory Bowel Disease through upstream modulation.<\/p>\n <\/div>\n <div><h4>Science<\/h4><ul>\n <li><a href=\"science.html\">Mechanism of Action<\/a><\/li>\n <li><a href=\"science.html#pipeline\">Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <\/ul><\/div>\n <div><h4>Company<\/h4><ul>\n <li><a href=\"about.html\">About<\/a><\/li>\n <li><a href=\"about.html#team\">Team<\/a><\/li>\n <li><a href=\"investors.html\">Investors<\/a><\/li>\n <\/ul><\/div>\n <div><h4>Contact<\/h4><ul>\n <li><a href=\"contact.html\">General Inquiries<\/a><\/li>\n <li><a href=\"contact.html#partnership\">Partnerships<\/a><\/li>\n <li><a href=\"contact.html#investors\">Investor Relations<\/a><\/li>\n <\/ul><\/div>\n <\/div>\n <div class=\"foot-copy\">\n <span>\u00a9 2026 Azuriya Pharma. All rights reserved.<\/span>\n <span>APX3330 is an investigational compound and has not been approved by any regulatory authority.<\/span>\n <\/div>\n <\/div>\n<\/footer>\n\n\n<script>\n(function(){\n var nav = document.querySelector('.nav');\n var toggle = document.querySelector('.nav-toggle');\n if (!nav || !toggle) return;\n toggle.addEventListener('click', function(){ nav.classList.toggle('is-open'); });\n var mobileLinks = nav.querySelectorAll('.nav-mobile a');\n mobileLinks.forEach(function(a){\n a.addEventListener('click', function(){ nav.classList.remove('is-open'); });\n });\n})();\n<\/script>\n\n<\/body>\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Science & Pipeline \u2014 Azuriya Pharma Home Science & Pipeline Publications About Investors Contact Home Science & Pipeline Publications About Investors Contact Science Upstream modulation.One target. Many diseases. APX3330 is a first-in-class oral inhibitor of APE1\/Ref-1 \u2014 the master regulator of transcription factors central to IBD disease progression. The mechanism fills gaps in current standard …<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_canvas","meta":{"_genesis_block_theme_hide_title":false,"footnotes":""},"class_list":["post-10","page","type-page","status-publish","hentry","post","without-featured-image"],"featured_image_src":null,"featured_image_src_square":null,"_links":{"self":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages\/10","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10"}],"version-history":[{"count":0,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages\/10\/revisions"}],"wp:attachment":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}